New light adjustable lenses results

Article

A small German study of light adjustable lenses (LALs) implanted in 10 eyes in 7 patients has produced positive results, according to the lens's manufacturer, Calhoun Vision.

A small German study of light adjustable lenses (LALs) implanted in 10 eyes in 7 patients has produced positive results, according to the lens's manufacturer, Calhoun Vision.

The LAL allows the doctor to adjust and refine the refraction following implantation using a Vision Light Delivery device, which is an ultra light system. Doctors are able to set the refractive correction to suit the specific visual needs of their patient prior to undertaking the final procedure to set the correction.

Published in the May issue of the Journal of Refractive Surgery the Klinik und Poliklinik für Augenheilkunde in Munich, Germany the initial results, at two weeks postoperatively, before the first light adjustment was made the mean refraction was +0.78 D, ±0.79 D. After the initial adjustment, the mean refraction improved to -0.07 D, ±0.21 D. Four eyes were treated with a second adjustment. At 1 month postoperative, all eyes were within ±0.50 D of the targeted refraction, with a mean uncorrected distance visual acuity of 1.02. All eyes gaining at least two lines of corrected distance visual acuity.

Results presented at ARVOA poster, which was presented by the Optics Laboratory of the University of Murcia and the Department of Ophthalmology at the University Hospital, Virgen de la Arrixaca, Murcia, Spain, at the recent ARVO meeting reported on monovision and asphericity results in patients implanted bilaterally with the LAL. In the monovision study, 8 patients had one eye adjusted for emmetropia with the fellow eye adjusted for myopia. The final mean refraction in the emmetropia eyes ranged from 0.00D to -0.75 D, and in the myopic eyes from -1.75 D to -2.25 D. The researchers pointed out that with the LAL, if a patient could not tolerate monovision, then the treatment could be reversed in the myopic eye and set to emmetropia – something that cannot be done with a non-adjustable IOL.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.